Global Latent Tuberculosis Infection (LTBI) Testing Market Growth (Status and Outlook) 2023-2029

Global Latent Tuberculosis Infection (LTBI) Testing Market Growth (Status and Outlook) 2023-2029

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.
Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.
LPI (LP Information)' newest research report, the “Latent Tuberculosis Infection (LTBI) Testing Industry Forecast” looks at past sales and reviews total world Latent Tuberculosis Infection (LTBI) Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Latent Tuberculosis Infection (LTBI) Testing sales for 2023 through 2029. With Latent Tuberculosis Infection (LTBI) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Latent Tuberculosis Infection (LTBI) Testing industry.
This Insight Report provides a comprehensive analysis of the global Latent Tuberculosis Infection (LTBI) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Latent Tuberculosis Infection (LTBI) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Latent Tuberculosis Infection (LTBI) Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Latent Tuberculosis Infection (LTBI) Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Latent Tuberculosis Infection (LTBI) Testing.
The global Latent Tuberculosis Infection (LTBI) Testing market size is projected to grow from US$ 1365.6 million in 2022 to US$ 2000 million in 2029; it is expected to grow at a CAGR of 5.6% from 2023 to 2029.
The detection industry of latent tuberculosis infection (LTBI) can be subdivided into several parts: tuberculin skin test (TST), interferon release test (IGRA), etc.
Globally, there are mainly Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis infection (LTBI) is an important strategy recognized by the World Health Organization to accelerate the decline of global tuberculosis and achieve the elimination of tuberculosis. Latent tuberculosis infection (LTBI) refers to the state of continuous immune response to the stimulation of Mycobacterium tuberculosis antigen in the absence of clinical evidence of active tuberculosis (TB). The diagnosis and treatment of long-term tuberculosis is very important for tuberculosis, especially for high-risk groups. Tuberculin skin tests (TST) and interferon release tests (IGRAs) were used to diagnose LTBI.
This report presents a comprehensive overview, market shares, and growth opportunities of Latent Tuberculosis Infection (LTBI) Testing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
Segmentation by application
Hospitals and Clinics
Diagnostic Laboratories
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Qiagen
Sanofi
Oxford Immunotec
Thermo Fisher Scientific
Par Sterile
Bio-Rad Laboratories

Please note: The report will take approximately 2 business days to prepare and deliver.